Search Results - "Yokosuka, Osamu"

De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes by Maruyama, Hitoshi, Okugawa, Hidehiro, Takahashi, Masanori, Yokosuka, Osamu

“…The objective of this study is to investigate predictive factors and long-term outcomes of de novo portal vein thrombosis (PVT) in cirrhosis. The incidence and…”
Get full text

Exosomes and Hepatocellular Carcinoma: From Bench to Bedside by Sasaki, Reina, Kanda, Tatsuo, Yokosuka, Osamu, Kato, Naoya, Matsuoka, Shunichi, Moriyama, Mitsuhiko

“…As hepatocellular carcinoma (HCC) usually occurs in the background of cirrhosis, which is an end-stage form of liver diseases, treatment options for advanced…”
Get full text

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial by Bruix, Jordi, Dr, Qin, Shukui, Prof, Merle, Philippe, Prof, Granito, Alessandro, MD, Huang, Yi-Hsiang, Prof, Bodoky, György, MD, Pracht, Marc, MD, Yokosuka, Osamu, Prof, Rosmorduc, Olivier, Prof, Breder, Valeriy, MD, Gerolami, René, Prof, Masi, Gianluca, MD, Ross, Paul J, FRCP, Song, Tianqiang, PhD, Bronowicki, Jean-Pierre, Prof, Ollivier-Hourmand, Isabelle, MD, Kudo, Masatoshi, Prof, Cheng, Ann-Lii, Prof, Llovet, Josep M, Prof, Finn, Richard S, MD, LeBerre, Marie-Aude, MSc, Baumhauer, Annette, MD, Meinhardt, Gerold, MD, Han, Guohong, Prof

“…Summary Background There are no systemic treatments for patients with hepatocellular carcinoma (HCC) whose disease progresses during sorafenib treatment. We…”
Get full text

Cancer stem cells in hepatocellular carcinoma: Therapeutic implications based on stem cell biology by Chiba, Tetsuhiro, Iwama, Atsushi, Yokosuka, Osamu

“…Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most frequent cause of cancer‐related death worldwide. Despite advances in its…”
Get full text

Androgen receptor signaling in hepatocellular carcinoma and pancreatic cancers by Kanda, Tatsuo, Jiang, Xia, Yokosuka, Osamu

“…Hepatocellular carcinoma(HCC)and pancreatic cancer remain difficult to treat,and despite the ongoing development of new treatments,the overall survival rate…”
Get full text

Hepatitis C virus NS5A inhibitors and drug resistance mutations by Nakamoto, Shingo, Kanda, Tatsuo, Wu, Shuang, Shirasawa, Hiroshi, Yokosuka, Osamu

“…Some direct-acting antiviral agents for hepatitis C virus(HCV),such as telaprevir and boceprevir have been available since 2011.It was reported that HCV NS5A…”
Get full text

Role of contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: evidence from a 10-year experience by Maruyama, Hitoshi, Sekimoto, Tadashi, Yokosuka, Osamu

“…Hepatocellular carcinoma (HCC) represents primary liver cancer. Because the development of HCC limits the prognosis as well as the quality of life of the…”
Get full text

Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization by Ogasawara, Sadahisa, Chiba, Tetsuhiro, Ooka, Yoshihiko, Kanogawa, Naoya, Motoyama, Tenyu, Suzuki, Eiichiro, Tawada, Akinobu, Kanai, Fumihiko, Yoshikawa, Masaharu, Yokosuka, Osamu

“…We compared the benefits of sorafenib therapy with continued transarterial chemoembolization (TACE) in TACE-refractory patients with intermediate-stage…”
Get more information

Nonalcoholic fatty liver disease and hepatic cirrhosis: comparison with viral hepatitis-associated steatosis by Haga, Yuki, Kanda, Tatsuo, Sasaki, Reina, Nakamura, Masato, Nakamoto, Shingo, Yokosuka, Osamu

“…Nonalcoholic fatty liver disease(NAFLD) including nonalcoholic steatohepatitis(NASH) is globally increasing and has become a world-wide health problem. Chronic…”
Get full text

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial by Mizokami, Masashi, Prof, Yokosuka, Osamu, Prof, Takehara, Tetsuo, Prof, Sakamoto, Naoya, Prof, Korenaga, Masaaki, MD, Mochizuki, Hitoshi, MD, Nakane, Kunio, MD, Enomoto, Hirayuki, MD, Ikeda, Fusao, MD, Yanase, Mikio, MD, Toyoda, Hidenori, MD, Genda, Takuya, MD, Umemura, Takeji, MD, Yatsuhashi, Hiroshi, Prof, Ide, Tatsuya, MD, Toda, Nobuo, MD, Nirei, Kazushige, Ueno, Yoshiyuki, Prof, Nishigaki, Yoichi, MD, Betular, Juan, BS, Gao, Bing, PhD, Ishizaki, Akinobu, BA, Omote, Masa, PhD, Mo, Hongmei, MD, Garrison, Kim, PhD, Pang, Phillip S, MD, Knox, Steven J, BS, Symonds, William T, PharmD, McHutchison, John G, MD, Izumi, Namiki, Prof, Omata, Masao, Prof

“…Summary Background Compared with other countries, patients with chronic hepatitis C infection in Japan tend to be older, have more advanced liver disease, and…”
Get full text

Nationwide survey for acute liver failure and late-onset hepatic failure in Japan by Nakao, Masamitsu, Nakayama, Nobuaki, Uchida, Yoshihito, Tomiya, Tomoaki, Ido, Akio, Sakaida, Isao, Yokosuka, Osamu, Takikawa, Yasuhiro, Inoue, Kazuaki, Genda, Takuya, Shimizu, Masahito, Terai, Shuji, Tsubouchi, Hirohito, Takikawa, Hajime, Mochida, Satoshi

“…Background A nationwide survey was performed to clarify the recent status of acute liver failure (ALF) and late-onset hepatic failure (LOHF) in Japan. Methods…”
Get full text

Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis by Fujiwara, Keiichi, Fukuda, Yoshihiro, Yokosuka, Osamu

“…Background The diagnosis of acute-onset autoimmune hepatitis (AIH) has been difficult because patients do not always show clinicopathological features typical…”
Get full text

Side population purified from hepatocellular carcinoma cells harbors cancer stem cell–like properties by Chiba, Tetsuhiro, Kita, Kaoru, Zheng, Yun‐Wen, Yokosuka, Osamu, Saisho, Hiromitsu, Iwama, Atsushi, Nakauchi, Hiromitsu, Taniguchi, Hideki

“…Recent advances in stem cell biology enable us to identify cancer stem cells in solid tumors as well as putative stem cells in normal solid organs. In this…”
Get full text

High recovery rate of consciousness by high‐volume filtrate hemodiafiltration for fulminant hepatitis by Fujiwara, Keiichi, Abe, Ryuzo, Yasui, Shin, Yokosuka, Osamu, Kato, Naoya, Oda, Shigeto

“…Aim An artificial liver support (ALS) system sustaining patients with acute liver failure (ALF) in good condition until recovery of the native liver or…”
Get full text

Clinicopathological features of severe and fulminant forms of autoimmune hepatitis by Yasui, Shin, Fujiwara, Keiichi, Yonemitsu, Yutaka, Oda, Shigeto, Nakano, Masayuki, Yokosuka, Osamu

“…Background and aims Diagnosis of the acute presentation of autoimmune hepatitis (AIH) is difficult because patients do not always show typical…”
Get full text

Proposed diagnostic criteria for acute‐on‐chronic liver failure in Japan by Mochida, Satoshi, Nakayama, Nobuaki, Ido, Akio, Inoue, Kazuaki, Genda, Takuya, Takikawa, Yasuhiro, Sakaida, Isao, Terai, Shuji, Yokosuka, Osamu, Shimizu, Masahito, Takikawa, Hajime

“…To establish diagnostic criteria for acute‐on‐chronic liver failure (ACLF) in Japan, the Intractable Hepato‐Biliary Disease Study Group of Japan undertook a…”
Get full text

A randomized placebo‐controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization by Ogasawara, Sadahisa, Chiba, Tetsuhiro, Ooka, Yoshihiko, Kanogawa, Naoya, Motoyama, Tenyu, Suzuki, Eiichiro, Tawada, Akinobu, Nagai, Kazue, Nakagawa, Tomoo, Sugawara, Takeshi, Hanaoka, Hideki, Kanai, Fumihiko, Yokosuka, Osamu

“…This randomized, double‐blind, placebo‐controlled trial evaluated dexamethasone efficacy at preventing fever, anorexia, and nausea/vomiting, the most frequent…”
Get full text

Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines by Haga, Yuki, Kanda, Tatsuo, Nakamura, Masato, Nakamoto, Shingo, Sasaki, Reina, Takahashi, Koji, Wu, Shuang, Yokosuka, Osamu

“…Despite recent advances in treatment strategies, it is still difficult to cure patients with hepatocellular carcinoma (HCC). Sorafenib is the only approved…”
Get full text

Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma by Chiba, Tetsuhiro, Saito, Tomoko, Yuki, Kaori, Zen, Yoh, Koide, Shuhei, Kanogawa, Naoya, Motoyama, Tenyu, Ogasawara, Sadahisa, Suzuki, Eiichiro, Ooka, Yoshihiko, Tawada, Akinobu, Otsuka, Masayuki, Miyazaki, Masaru, Iwama, Atsushi, Yokosuka, Osamu

“…Histone H3 lysine 9 trimethylation (H3K9me3) is associated with transcriptional repression and regulated by histone lysine methyltransferases such as SUV39H1…”
Get full text

Key HLA‐DRB1‐DQB1 haplotypes and role of the BTNL2 gene for response to a hepatitis B vaccine by Nishida, Nao, Sugiyama, Masaya, Sawai, Hiromi, Nishina, Sohji, Sakai, Aiko, Ohashi, Jun, Khor, Seik‐Soon, Kakisaka, Keisuke, Tsuchiura, Takayo, Hino, Keisuke, Sumazaki, Ryo, Takikawa, Yasuhiro, Murata, Kazumoto, Kanda, Tatsuo, Yokosuka, Osamu, Tokunaga, Katsushi, Mizokami, Masashi

“…Approximately 5‐10% of individuals who are vaccinated with a hepatitis B (HB) vaccine designed based on the hepatitis B virus (HBV) genotype C fail to acquire…”
Get full text